Credibility Analysis webpage.

<p>Credibility Analysis webpage.</p

Intramuscular nerve axons in EOMs.

<p>Light microscopic images of nerve axons from adult and elderly controls and from ALS donors treated with antibodies against NF-L (A), S100B (B), GFAP (C) and p75^NTR (D). Note the absence of S100B in the nerve axons (B3, outlined area) in the ALS donor. Bars = 40 µm.</p

NF-L and synaptophysin at NMJs of EOMs.

<p>Light microscopic images of NMJs from adult controls (A and C) and ALS donors (B and D) double-labeled with α-bungarotoxin (BTx, red) and antibodies against NF-L (green; A1, A3, B1, and B3) or synaptophysin (green; C1, C3, D1 and D3). Note the similar staining patterns between controls and ALS donors. Bar = 20 µm.</p

Overview of credibility analysis method.

<p>Overview of credibility analysis method.</p

S100B, GFAP and p75^NTR at NMJs of EOMs.

<p>Confocal images of NMJs from adult controls (A, C, and E) and ALS donors (B, D and F) double-labeled with antibodies (green) against S100B (A, B), GFAP (C, D) and p75^NTR (E, F) and α-bungarotoxin (BTx, red in A and B) or antibody against AChR (red in C–F). Note the similar staining patterns between controls and ALS donors with all antibodies, with the exception of S100B. Arrowheads in B denote lack of staining. Bar = 24 µm.</p

Characteristics of ALS donors and extraocular (EOM) and limb muscles examined in each donor.

*<p>The donors were numbered according to the order in which they were collected for EOM vs limb studies. For consistency with the previous donor numbers <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0057473#pone.0057473-Ahmadi1" target="_blank">[6]</a>, the newly added and earliest donor of limb muscle only was named Da.</p><p>RS, rectus superior; RL, rectus lateralis; RM, rectus medialis; OS, obliquus superior; VL, vastus lateralis; BB, biceps brachii; TA, tibialis anterior. The total number of samples studied is given in brackets. wt = wild type phenotype.</p

Risk of bronchopneumonia under NIV.

<p>Risk of bronchopneumonia under NIV.</p

Autopsy confirmed causes of death in %.

<p>Autopsy confirmed causes of death in %.</p

Characteristic of the autopsy cohort.

<p>Characteristic of the autopsy cohort.</p

Percentage of NMJs labeled with anti-NF-L, -synaptophysin, -S100B, -GFAP or p75^NTR in limb muscles of ALS and controls.

a<p>Two separate muscle samples from biceps brachii were examined from donor 3.</p>*<p>Denotes statistically significant difference between both ALS donors and adult controls and between ALS donors and elderly controls.</p>**<p>Denotes statistically significant difference between adult control and elderly control (p<0.05).</p><p>N: the number of NMJs examined; n: the number of control subjects studied; SYP: synaptophysin.</p